A New York City radiation oncologist who specializes in fractionated stereotactic radiosurgery and stereotactic body radiation therapy agreed to pay $2.35 million to resolve a 10-year-old Medicare fraud lawsuit.
NCI has published the bypass budget for the fiscal year 2016, asking for $5.754 billion, an $823 million increase over the estimated budget of $4.931 billion.
The Centers for Medicare & Medicaid Services issued its final payment decision regarding the Cologuard stool DNA colorectal cancer screening test, and will reimburse it at $502 per test.
FDA granted clearance for IQQA-BodyImaging, developed by EDDA Technology, as the latest addition to the IQQA platform and product suite for imaging-guided cancer treatment.
The Broad Institute, Harvard University, the Massachusetts Institute of Technology and Editas Medicine entered into a worldwide license agreement to grant Editas access to intellectual property related to the the CRISPR-Cas9 system genome editing technology.
Top NCI officials made an unusual assurance that the reorganization of clinical trials cooperative groups isn't a “prelude to reducing the commitment of the NCI to clinical trials-based research.”
ASTRAZENECA, Pharmacyclics Inc. and Janssen Research & Development LLC entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Imbruvica (ibrutinib).
DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.
THE HARRINGTON DISCOVERY INSTITUTE at University Hospitals and the University of Oxford formed an affiliation focused on drug discovery projects.
ANTJE HOERING was named CEO of Cancer Research and Biostatistics, effective Jan. 1, 2015.
